Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jingshu granules is a Traditional Chinese Medicine (TCM) formulation developed by Shandong Haihui Bioengineering Co., Ltd. for the treatment of primary dysmenorrhea. It is specifically designed to address the Cold-Damp Stagnation pattern, a common TCM diagnosis for painful menstruation. The drug is a multi-herb combination that works by promoting blood circulation and relieving pain through the modulation of uterine contractions and inflammatory mediators. Clinical development in China reached Phase III, where it was evaluated for its ability to reduce the severity of menstrual cramps and improve the quality of life for women with primary dysmenorrhea. As a modernized TCM, it is processed into a granule form for oral administration, providing a standardized dosage of the active herbal constituents.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on jingshu granules.